Skip to content
Inciteful Med
Resources About us Ask a Question

Sjögren's Lymphoma Risk: Warning Signs | Inciteful Med

Published: | Updated:

People with Sjögren's syndrome have a 5-10% lifetime risk of developing Non-Hodgkin lymphoma, usually MALT lymphoma. Key warning signs include salivary glands that become permanently hard or swollen, drenching night sweats, unexplained weight loss, and blood markers like low C4 levels.

Key Takeaways

  • • Most people with Sjögren's syndrome will not develop lymphoma, but there is an elevated 5-10% lifetime risk.
  • • The most common type of lymphoma in Sjögren's is a slow-growing Non-Hodgkin lymphoma known as MALT lymphoma.
  • • Salivary glands that become persistently swollen, stop fluctuating in size, or feel hard to the touch are key warning signs.
  • • Systemic red flags include unexplained weight loss, drenching night sweats, and recurring fevers.
  • • Rheumatologists track specific lab markers like low C4 levels and cryoglobulins to monitor your risk during regular check-ups.

If you have primary Sjögren’s syndrome, one of the most concerning complications you might worry about is the risk of developing lymphoma. The direct answer is that while most people with Sjögren’s will never develop lymphoma, there is a 5-10% lifetime risk of developing a type of blood cancer called Non-Hodgkin lymphoma [1][2]. The most critical warning signs that your condition may be changing include persistently swollen salivary glands that feel hard or do not shrink over time, unexplained weight loss, drenching night sweats, and new rashes [3][4][1]. Knowing these “red flags” empowers you to monitor your body between doctor visits and seek prompt medical attention if things change.

The Most Common Type: MALT Lymphoma

When lymphoma does occur in Sjögren’s syndrome, the most common type is a slow-growing form of Non-Hodgkin lymphoma known as Mucosa-Associated Lymphoid Tissue (MALT) lymphoma [5][6]. Because Sjögren’s primarily affects your moisture-producing glands, MALT lymphoma often develops right within the salivary glands themselves [1][7]. It is generally very treatable, but requires proper diagnosis and care [8][9]. Another, less common type is Diffuse Large B-cell Lymphoma (DLBCL), which tends to be faster-growing [5][10].

Clinical Red Flags to Watch For

Because your risk is elevated compared to the general population [11][12], it is vital to know the physical signs to monitor. Do not panic if you experience one of these, but do contact your doctor for an evaluation:

  • Persistently Swollen Salivary Glands: Swelling in the glands around your face and neck (especially the parotid glands near your jaw) is a normal symptom of Sjögren’s. However, if the swelling is persistent, continues to grow, does not fluctuate in size, or becomes firm and hard to the touch, it is a key warning sign that warrants investigation [13][3][14].
  • Systemic “B-Symptoms”: This is a medical term for a specific cluster of full-body symptoms linked to lymphoma [3][4]. They include:
    • Unexplained Weight Loss: Dropping weight without changing your diet or exercise routine.
    • Night Sweats: Drenching sweats that soak through your sleepwear and bedsheets.
    • Recurring Fevers: Fevers that come and go without an obvious infection.
  • Swollen Lymph Nodes: New, painless lumps under your skin in your neck, armpits, or groin, known as lymphadenopathy [3][15].
  • Skin Rashes (Purpura): A specific type of rash made of small, non-blanching red or purple spots, usually on the lower legs, which indicates blood vessel inflammation [16][17].

Laboratory Risk Factors

Beyond physical symptoms, your rheumatologist will monitor your bloodwork for “invisible” signs that put you at higher risk. These include:

  • Low C4 Levels: A drop in certain immune system proteins (complement) that are part of your body’s defense network [18][19].
  • Cryoglobulinemia: The presence of abnormal proteins in the blood that thicken in cold temperatures [16][17].
  • Monoclonal Gammopathy: An abnormal spike in a specific type of antibody protein [18][19].

You typically do not need to ask for these tests by name, as tracking complement and immunoglobulins is standard rheumatology practice for Sjögren’s care. However, because laboratory markers can shift before physical symptoms appear, it is important to maintain regular check-ups (usually every 6 to 12 months) even if you feel completely fine [1][20]. If you have these markers, your doctor may monitor you more closely, possibly using ultrasound imaging to check the health of your salivary glands [3][14].

When to Contact Your Doctor

If you notice your glands have stayed swollen for longer than usual, or if they feel like hard nodules rather than soft swelling, do not wait for your next scheduled appointment [21][3]. You do not need to go to the emergency room, but you should call your rheumatologist to schedule an evaluation soon. They can perform an ultrasound or a biopsy to see exactly what is happening [8][22]. Catching any changes early drastically improves your options.

Frequently Asked Questions

What is the risk of getting lymphoma if I have Sjögren's syndrome?
Most people with Sjögren's syndrome will never develop lymphoma. However, there is a 5-10% lifetime risk of developing Non-Hodgkin lymphoma, most commonly a slow-growing type called MALT lymphoma.
What are the physical warning signs of lymphoma in Sjögren's?
Key warning signs include salivary glands that are persistently swollen, feel hard to the touch, or do not fluctuate in size. Other systemic signs to watch for are unexplained weight loss, drenching night sweats, recurring fevers, and new skin rashes.
Are there blood test results that indicate a higher risk for lymphoma?
Yes, rheumatologists monitor for specific blood markers like low C4 complement levels, cryoglobulins, and monoclonal gammopathy. These laboratory changes can indicate a higher risk and often appear before any physical symptoms occur.
What should I do if I notice a hard lump in my salivary gland?
You should contact your rheumatologist promptly for an evaluation rather than waiting for your next scheduled appointment. They may recommend an ultrasound or a biopsy to accurately determine what is causing the change in your gland.

Questions for Your Doctor

  • • Are there specific blood markers, like low C4 or cryoglobulins, that you are currently monitoring to assess my lymphoma risk?
  • • Given my current symptoms and lab work, do I fall into a higher-risk category for MALT lymphoma?
  • • Would a baseline ultrasound of my major salivary glands be useful for tracking changes over time?
  • • If I notice a firm nodule or persistent swelling in my salivary gland, how quickly should I contact your office for an evaluation?

Questions for You

  • • Have I experienced any sudden, unexplained weight loss or woke up drenched in sweat recently?
  • • Are my salivary glands currently swollen, and if so, do they feel harder, firmer, or less fluctuant than they used to?
  • • Have I noticed any new red or purple spots on my lower legs that don't fade when I press on them?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Predicting lymphoma development in patients with Sjögren's syndrome.

    De Vita S, Gandolfo S

    Expert review of clinical immunology 2019; (15(9)):929-938 doi:10.1080/1744666X.2019.1649596.

    PMID: 31347413
  2. 2

    Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences.

    Vasaitis L, Nordmark G, Theander E, et al.

    Scandinavian journal of rheumatology 2020; (49(3)):225-232 doi:10.1080/03009742.2019.1696403.

    PMID: 32153241
  3. 3

    Lymphoma in Sjögren's syndrome: no need for repetitive screening ultrasounds of the major salivary glands and neck in asymptomatic patients.

    Hüper S, Nagler L, Strunz PP, et al.

    Scandinavian journal of rheumatology 2025; (54(1)):49-57 doi:10.1080/03009742.2024.2370109.

    PMID: 39007819
  4. 4

    Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome.

    Vasaitis L, Nordmark G, Theander E, et al.

    Scandinavian journal of rheumatology 2019; (48(3)):207-212 doi:10.1080/03009742.2018.1523456.

    PMID: 30422723
  5. 5

    Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome.

    Gorodetskiy VR, Probatova NA, Vasilyev VI

    International journal of rheumatic diseases 2020; (23(4)):540-548 doi:10.1111/1756-185X.13800.

    PMID: 32100426
  6. 6

    Cutaneous mucosa-associated lymphoid tissue lymphoma complicating Sjögren's syndrome: A case report and review of literature.

    Liu Y, Zhu J, Huang YH, et al.

    World journal of clinical cases 2022; (10(14)):4509-4518 doi:10.12998/wjcc.v10.i14.4509.

    PMID: 35663092
  7. 7

    Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study.

    Goules AV, Chatzis L, Pezoulas VC, et al.

    The Lancet. Rheumatology 2024; (6(10)):e693-e702 doi:10.1016/S2665-9913(24)00183-8.

    PMID: 39182505
  8. 8

    Ultrasound-Guided Biopsy of Suspected Salivary Gland Lymphoma in Sjögren's Syndrome.

    Baer AN, Grader-Beck T, Antiochos B, et al.

    Arthritis care & research 2021; (73(6)):849-855 doi:10.1002/acr.24203.

    PMID: 32248649
  9. 9

    Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review.

    Tesher MS, Esteban Y, Henderson TO, et al.

    Journal of pediatric hematology/oncology 2019; (41(5)):413-416 doi:10.1097/MPH.0000000000001321.

    PMID: 30371536
  10. 10

    Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina.

    Brom M, Moyano S, Gandino IJ, et al.

    Rheumatology international 2019; (39(10)):1697-1702 doi:10.1007/s00296-019-04433-2.

    PMID: 31471716
  11. 11

    Lymphoma and Sjögren Syndrome: A Common Overlapping Syndrome?

    Chen YW, Tsai PY, Wei JC

    The Journal of rheumatology 2021; (48(8)):1343 doi:10.3899/jrheum.201537.

    PMID: 33993105
  12. 12

    Bidirectional Relationship Between Primary Sjögren Syndrome and Non-Hodgkin Lymphoma: A Nationwide Taiwanese Population-based Study.

    Wang LH, Wang WM, Lin CY, et al.

    The Journal of rheumatology 2020; (47(9)):1374-1378 doi:10.3899/jrheum.191027.

    PMID: 31941803
  13. 13

    Hypokalemic Paralysis Due to Primary Sjogren Syndrome.

    Sarma A

    Indian journal of endocrinology and metabolism 2018; (22(2)):287-289 doi:10.4103/ijem.IJEM_666_17.

    PMID: 29911048
  14. 14

    Imaging in Primary Sjögren's Syndrome.

    van Ginkel MS, Glaudemans AWJM, van der Vegt B, et al.

    Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082492.

    PMID: 32756395
  15. 15

    Differences in clinical phenotypes of primary Sjögren's syndrome depending on early or late onset.

    Sebastian A, Madej M, Sebastian M, et al.

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2021; (30(11)):1141-1146 doi:10.17219/acem/140178.

    PMID: 34549557
  16. 16

    A lower prevalence of malignant lymphoma in Sjögren's syndrome patients: A cross-sectional study.

    Saleh W, Elashry MM, Winn N, et al.

    Oral diseases 2023; (29(8)):3313-3324 doi:10.1111/odi.14435.

    PMID: 36369668
  17. 17

    Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome.

    Tomi AL, Belkhir R, Nocturne G, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(5)):1245-50 doi:10.1002/art.39534.

    PMID: 26636425
  18. 18

    Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.

    Nocturne G, Virone A, Ng WF, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(4)):977-85 doi:10.1002/art.39518.

    PMID: 26606524
  19. 19

    Deep Immunophenotyping and Clustering Identifies Biomarkers Predictive of Lymphoma in Primary Sjögren Disease.

    Marques C, Régnier P, Maciejewski-Duval A, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(10)):1394-1406 doi:10.1002/art.43207.

    PMID: 40290096
  20. 20

    Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.

    Deng J, Liu M, Xiao R, et al.

    Frontiers in immunology 2022; (13()):904682 doi:10.3389/fimmu.2022.904682.

    PMID: 35844507
  21. 21

    The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.

    De Vita S, Gandolfo S, Zandonella Callegher S, et al.

    Clinical and experimental rheumatology 2018; (36 Suppl 112(3)):150-156.

    PMID: 30156548
  22. 22

    Primary Sjögren's syndrome initially presenting as submandibular mucosa-associated lymphoid tissue lymphoma: A case report.

    Chen LY, Tsai MH, Tsai LT, et al.

    Oncology letters 2016; (11(2)):921-924 doi:10.3892/ol.2015.3980.

    PMID: 26893669

This page provides information on lymphoma risk in Sjögren's syndrome for educational purposes only. Always consult your rheumatologist to evaluate new symptoms, changes in your salivary glands, or lab results.

Stay up to date

Get notified when new research about Primary Sjögren's Syndrome is published.

No spam. Unsubscribe anytime.